上皮性卵巢癌组织中TUBB3和ERCC1的表达

摘要

目的：通过检测TUBB3和ERCC1在上皮性卵巢癌组织中的表达情况，探讨两者与上皮性卵巢癌化疗疗效及预后的关系。方法采用免疫组化技术检测25例正常卵巢组织和50例上皮性卵巢癌组织中TUBB3和ERCC1蛋白的表达情况。结果 TUBB3和ERCC1在上皮性卵巢癌组织中的阳性率明显高于正常卵巢组织（ P﹤0.05），两者的阳性表达率与上皮性卵巢癌的分化程度及临床分期有关。上皮性卵巢癌组织中TUBB3和ERCC1蛋白表达呈正相关关系（r＝0.332，P﹤0.05）。TUBB3、ERCC1阳性表达患者化疗有效率分别为34.6%和31.4%，均明显低于阴性患者的91.7%和93.3%（P﹤0.05）。结论上皮性卵巢癌组织中TUBB3、ERCC1的表达可能影响化疗疗效及其预后存，两者阳性表达可能提示上皮性卵巢癌化疗耐药，可作为上皮性卵巢癌化疗耐药和预后检测的重要指标。%Objective By detecting β-tubulin-Ⅲ(TUBB3)and excision repair cross complement group 1(ER-CC1)protein expressions in the epithelial ovarian cancer,to explore the relationship with the chemotherapy curative effect and prognosis of epithelial ovarian cancer. Methods Immunohistochemistry technique was used to detect the TUBB3 and ERCC1 protein expressions in the 25 cases of normal ovarian tissues and the 50 cases of epithelial ovari-an cancer. Results TUBB3 and ERCC1 protein expressions in the epithelial ovarian cancer was significantly higher than those in the normal ovarian tissues(P﹤0. 05). Their positive expression rates were related to the differentiation degree and the clinical stage of epithelial ovarian cancer(P﹤0. 05). TUBB3 protein expression was positively relat-ed with ERCC1 protein expression in the epithelial ovarian cancer(r=0. 332,P﹤0. 05). The chemotherapy efficacy rate of patients with TUBB3 or ERCC1 positive(34. 6% and 31. 4%)were lower than those of patients with TUBB3 or ERCC1 negative(91. 7% and 93. 3%)(P﹤0. 05). Conclusion TUBB3 and ERCC1 protein expressions in ep-ithelial ovarian cancer can be related to the chemotherapy efficacy and the prognosis,the two positive expressions may indicate chemotherapy drug resistance of epithelial ovarian cancer,can be used as an important index for chem-otherapy drug resistance and prognosis of epithelial ovarian cancer.